ood morning, folks, and how are you today? We apologize for the late arrival, but we are still on an altered schedule as we roam about the J.P. Morgan Healthcare Conference, a sort of Woodstock for biopharma enthusiasts. And yes, we are slogging through with help from cups of stimulation and rounds of interesting chatter. But enough about us. Here are a few items of interest to help you along on your own furtive missions. Hope you have a smashing day and, as always, do stay in touch. We welcome your outreach …

The Food and Drug Administration granted priority review for combining Merck’s Keytruda immunotherapy with chemotherapy as an initial treatment for advanced lung cancer. “This comes as an important surprise because if FDA approves the application, Merck would suddenly be catapulted ahead of all other competitors who are also pursuing competing combination regimens of their own,” Bernstein analyst Tim Anderson wrote investors.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ed, since you are at a Woodstockian event I would remind you of the admonition of Woodstock emcee Chip Moncke: “Don’t eat the brown acid”.

    • Sound advice, pv1, but may I observe that you are well over 30? Most probably, he won’t trust you – ah, ‘foolish youth!’

  • Now that Sarepta has cheers investor$, when will or how soon will it ‘cheer’ the regulators (and the paying public) by generating follow-on (aka Phase 4) data to show that it really is effective and not just $afe? On the other hand, I appreciate that it would be difficult to possibly jeopardize one’s perceived status as holder of the world’s most expensive placebo.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.